X4 Pharmaceuticals Announces Presentation of Positive Data from Ongoing Phase 1b Clinical Trial of Mavorixafor in Waldenström's Macroglobulinemia at EHA 2021
Robust decreases in serum IgM at low- and mid-doses suggest best-in-class potential for
At 6 months, patients achieved median IgM level reductions of 60%-75%, with
e-Poster now available online; pre-recorded presentation by lead author Dr. Steven Treon
Conference call and webcast today at 7:00 am ET with X4 management and
BOSTON, June 11, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced positive preliminary efficacy and safety data from its ongoing Phase 1b clinical trial of its lead candidate mavorixafor, in combination with ibrutinib, in Waldenström’s macroglobulinemia patients with both MYD88 and CXCR4 mutations. These data are included in a poster published today at this year’s European Hematology Association (EHA) Annual Congress.
“We are very pleased to present this exciting first look at the data from our ongoing Phase 1b trial in double-mutation Waldenström’s patients,” said Diego Cadavid, M.D., Chief Medical Officer of X4 Pharmaceuticals. “Despite still being in the low- and mid-dose ranges of mavorixafor, we are already seeing robust decreases in IgM levels – an important signal of clinical response – showing the potential benefit for mavorixafor in combination with ibrutinib. The combination therapy is demonstrating good tolerability and promising results across additional pharmacodynamic parameters, including increases in total hemoglobin and mobilization of white blood cells. We look forward to presenting longer-term data and an expanded data set from this trial later in the year.”
“While ibrutinib has significantly advanced the treatment of Waldenström’s macroglobulinemia, we have observed that there remains a clinical unmet need for patients with concurrent CXCR4 and MYD88 mutations,” said Steven Treon, M.D., Ph.D., FACP, FRCP, Director of the Bing Center for Waldenström's Macroglobulinemia at Dana-Farber Cancer Institute, Professor of Medicine at Harvard Medical School, and the poster’s lead author. “I am encouraged by the preliminary safety and efficacy data from the ongoing combination trial of ibrutinib and mavorixafor in this difficult-to-treat patient population and look forward to continuing this important research.”
Key Highlights of the Preliminary Low- and Mid-Dose Phase 1b Results
The e-poster (EP784) entitled: “Preliminary Clinical Data From a Phase 1b Study of Mavorixafor and Ibrutinib in Patients With Waldenström’s Macroglobulinemia With MYD88 and CXCR4 Mutations” is now available on the X4 corporate website. Conference attendees can access an accompanying audio presentation by Dr. Treon on the Congress website.
X4 will host a conference call and webcast at 7:00 am ET today that will include presentations by X4 senior executives and a “Fireside Chat” and Q&A with poster co-author Christian Buske, M.D., Director of the Institute of Experimental Cancer Research and Attending Physician, Senior Consultant at the University Hospital of Ulm, and Founder and Coordinator of the European Consortium for Waldenström’s Macroglobulinemia.
The conference call can be accessed by dialing (866) 721-7655 (domestic) or (409) 216-0009 (international), followed by the conference ID: 4492859. The live webcast will be accessible on the Events & Presentations page of the company’s website at investors.x4pharma.com. The conference call slide deck will be made available upon completion of the event and the webcast replay will be available approximately two hours after the completion of the event on X4’s website.
This Phase 1b clinical trial is being conducted with the support of AbbVie Inc. and The Leukemia & Lymphoma Society’s Therapy Acceleration Program® (LLS TAP).
About Waldenström’s Macroglobulinemia and Associated CXCR4 Mutations
About Mavorixafor and the Phase1b Clinical Trial in Waldenström’s Macroglobulinemia
About X4 Pharmaceuticals
Investors and Media:
Mónica Rouco Molina
How to Use Asset Tracking to Enable The Smart Supply Chain: Fireside Chat w/ NimbeLink and Smart Logistics
Back Together Happy Hour - Welcome Networking Event - Sponsored by Telefonica
Great Customer Outcomes: A Balance Between Automation & Empathy